Acalabrutinib Plus Bendamustine and Rituximab in Untreated MCL: Results From the Phase 3 ECHO Trial : Episode 4
Unmet Needs and Key Takeaways: ECHO Clinical Trial
Medical experts evaluate unmet needs, key insights from the Phase 3 ECHO trial, and potential obstacles in integrating the findings into existing treatment protocols.
EP: 1.Brief Overview of Front-line treatment for Mantel Cell Lymphoma in Older Patients
EP: 2.Phase 3 ECHO Trial: Study Design and Efficacy Data
EP: 3.Phase 3 ECHO: Safety Data Review
Now Viewing
EP: 4.Unmet Needs and Key Takeaways: ECHO Clinical Trial
EP: 5.Integrating Acalabrutinib Plus Bendamustine/Rituximab in the Frontline MCL Treatment Protocol
- What is your standard of care (SOC) in this patient population?
- How does this regimen (BTKi+BR) compare in efficacy and safety to your SOC?
Recent Videos
Related Content
Prolaris in Practice: Guiding ADT Benefits, Clinical Application, and Expert Insights From ACRO 2025
April 15th 2025Podcast
Steven E. Finkelstein, MD, DABR, FACRO discuses how Prolaris distinguishes itself from other genomic biomarker platforms by providing uniquely actionable clinical information that quantifies the absolute benefit of androgen deprivation therapy when added to radiation therapy, offering clinicians a more precise tool for personalizing prostate cancer treatment strategies.
